The Evolving Spectrum of TNF Inhibitors in the Management of Psoriatic Disease

Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, discuss updates in the pathogenesis of PsA and PsO.

Drs Mark G. Lebwohl and Joseph F. Merola discuss how patient presentation differs in patients with PsO and PsA.

Expert dermatologists discuss challenges in diagnosing a patient with PsA.

Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, provide tips to overcome diagnostic delay in psoriasis.

Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, discuss different head-to-head studies in psoriasis.

Expert dermatologists discuss different anti-TNF molecules and the impact of having these types of molecules on psoriasis and psoriatic arthritis care.

Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, provide insight on when it is appropriate to switch from one biologic to another for a patient with psoriasis.

Drs Mark G. Lebwohl and Joseph F. Merola discuss the use of biosimilars in psoriasis and how biosimilars will change the treatment landscape.

Mark G. Lebwohl, MD, presents a case of a 45-year-old Caucasian male diagnosed with psoriasis.

Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, provide impressions to the case and take-home messages for dermatologists and rheumatologists treating psoriasis.